Pfizer Inc. (NYSE:PFE) Holdings Decreased by Bryn Mawr Capital Management LLC

Bryn Mawr Capital Management LLC cut its holdings in Pfizer Inc. (NYSE:PFE) by 4.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 68,885 shares of the biopharmaceutical company’s stock after selling 3,248 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in Pfizer were worth $1,746,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Norges Bank bought a new stake in Pfizer in the fourth quarter worth about $2,328,986,000. Starboard Value LP bought a new stake in Pfizer in the fourth quarter worth about $407,730,000. Assenagon Asset Management S.A. raised its position in Pfizer by 307.5% in the first quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company’s stock worth $254,574,000 after acquiring an additional 7,581,030 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after acquiring an additional 5,350,381 shares in the last quarter. Finally, APG Asset Management N.V. raised its position in Pfizer by 1,106.0% in the fourth quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company’s stock worth $143,967,000 after acquiring an additional 5,153,257 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Down 2.9%

Shares of NYSE PFE opened at $24.63 on Wednesday. The stock has a market cap of $140.00 billion, a price-to-earnings ratio of 17.84, a PEG ratio of 0.92 and a beta of 0.58. The business has a 50 day simple moving average of $23.95 and a 200 day simple moving average of $24.77. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm’s quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.82 EPS. On average, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.98%. Pfizer’s dividend payout ratio (DPR) is currently 124.64%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Morgan Stanley lifted their price target on Pfizer from $31.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 30th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Berenberg Bank dropped their price target on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Thursday, May 29th. Cantor Fitzgerald assumed coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target on the stock. Finally, Redburn Atlantic dropped their price target on Pfizer from $29.00 to $27.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.